Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

“For nearly a decade, Sarepta has been a leader in advancing the treatment of Duchenne muscular dystrophy through innovative treatment options. With the approval of ELEVIDYS in Japan, children ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has released new data from its ENDEAVOR study, showing encouraging results for its Duchenne muscular dystrophy treatment, ELEVIDYS. The latest cohort of ...

Elevidys is a prescription gene therapy developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). It targets the root cause of the disease by delivering a shortened but ...

Japanese MHLW approves Chugai’s Elevidys as a gene therapy product to treat Duchenne muscular dystrophy: Tokyo Thursday, May 15, 2025, 16:00 Hrs [IST] Chugai Pharmaceutical Co., ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

For nearly a decade, Sarepta has been a leader in advancing the treatment of Duchenne muscular dystrophy through innovative treatment options. With the approval of ELEVIDYS in Japan, children who ...